Vaccine News and Research

Latest Vaccine News and Research

"A shred of evidence" BCG vaccinations protect against COVID-19

Professor David Levine from the University of California, Berkeley, says a study of people in Spain and Italy has provided a “shred of evidence” that the BCG vaccination may protect against coronavirus disease 2019 (COVID-19).

9 Jun 2020

New model can estimate regional disease burden and impact of vaccination

Researchers have developed a model that can estimate regional disease burden and the impact of vaccination, even in the absence of robust surveillance data, a study in eLife reveals.

9 Jun 2020

Immune cell discovery could help develop new treatments for hepatitis B

For the first time, researchers at The Westmead Institute for Medical Research have identified and described a new and unique subset of human cells that are involved in the immune response against hepatitis B (HBV) infection. The discovery could help develop new treatments for HBV and inform future vaccine design.

9 Jun 2020

Scientists harness cancer immunotherapy tools to identify targets for COVID-19 vaccine

Cancer researchers at Children's Hospital of Philadelphia have harnessed tools used for the development of cancer immunotherapies and adapted them to identify regions of the SARS-CoV-2 virus to target with a vaccine, employing the same approach used to elicit an immune response against cancer cells to stimulate an immune response against the virus.

8 Jun 2020

Reflections and expectations: Are we handling COVID-19 in the right way?

COVID-19 Reflections: Severe lockdowns and Stay-at-Home orders have been hallmark of the national and global response to this Pandemic. They have been imposed with little precedent and scant evidence of their effectiveness as opposed to less restrictive social distancing measures.

8 Jun 2020

Census of viral spike protein antigens could benefit development of SARS-CoV-2 therapeutics

A group of researchers has determined how different proteins associated with SARS-CoV-2 - the virus that causes COVID-19 - generate immune responses when given to rabbits as immunizations.

8 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

Scientists find way to prevent warmed-up vaccines from degrading

Vaccines are notoriously difficult to transport to remote or dangerous places, as they spoil when not refrigerated.

8 Jun 2020

Inhibition of coronavirus spike protein binding to ACE2

A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.

8 Jun 2020

SARS-CoV-2 genome variants in India

A new study published online on the preprint server bioRxiv in June 2020 surveys the genetic diversity of SARS-CoV-2 strains in India.

7 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

Tear-gassing protesters during an infectious outbreak ‘a recipe for disaster’

In nationwide demonstrations sparked by the killing of George Floyd in police custody, protesters have been frequently pepper-sprayed or enveloped in clouds of tear gas.

5 Jun 2020

T cells can counteract dangerous phenomenon of mosquito-borne viruses

Every year, more than 68,000 people end up with a clinical case of Japanese encephalitis. One in four of these patients will die. The mosquito-borne virus, which is most common in Southeast Asia, also causes severe neurological damage and psychiatric disorders.

5 Jun 2020

A SARS-CoV-2 antibody magnetic immuno-detection test

A new report, released on the preprint server bioRxiv by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test that could provide a fast, easy, and inexpensive method of detecting high titers of antibody in the serum of SARS-CoV-2 infected people.

4 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Comparing genomes to understand how mutations affect the COVID-19 pandemic

Now, a new study by researchers at the Massachusetts Institute of Technology and the Center for Computational Biology, Flatiron Institute and published online on the bioRxiv preprint server describes how the use of comparative genomics helps to identify protein-coding and non-coding functional genes.

4 Jun 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

HPV vaccines that work in the U.S. may not be effective in protecting other populations of women

A research team at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center has found that the same vaccination programs that target human papillomavirus (hrHPV) strains in the United States may not be as effective in protecting other populations of women from the disease.

4 Jun 2020

New technology to monitor anti-drug antibodies in MS patients may have potential for COVID-19 testing

A new study led by Queen Mary University of London has demonstrated the effectiveness of using a novel light technology to monitor the presence of anti-drug antibodies in the treatment of multiple sclerosis, which can lead to drug resistance and treatment failure.

4 Jun 2020

New treatments for sleep apnea and other weak muscle conditions to be unveiled at global biotech event

A world-first therapeutic for treating sleep apnea and a range of other weak muscle conditions will be unveiled at global biotech innovation event, Bio Digital (June 8-12).

4 Jun 2020